Scleroderma Lung Study Ii: Comparison Of Therapy With Mycophenolate Mofetil Versus Oral Cyclophosphamide In Patients With Symptomatic Scleroderma Interstitial Lung Disease

被引：0
|
作者：
Tashkin, D. P. [1 ]
Roth, M. D. [1 ]
Furst, D. E. [1 ]
Clements, P. [1 ]
Khanna, D. [2 ]
Volkmann, E. [1 ]
Kalafa, S. [1 ]
Goldin, J. [3 ]
Kim, G. H. J. [3 ]
Arriola, E. [4 ]
Tseng, C. -H. [4 ]
Elashoff, R. E. [4 ]
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[2] Univ Michigan, Sch Med, Ann Arbor, MI USA
[3] David Gefen Sch IMed, Los Angeles, CA USA
[4] David Geffen Sch Med, Los Angeles, CA USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2016年 / 193卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A6432
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Cyclophosphamide for scleroderma lung disease
    Martinez, FJ
    McCune, WJ
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (25): : 2707 - 2709
  • [32] Treatment With Mycophenolate and Cyclophosphamide Leads to Clinically Meaningful Improvements in Patient-Reported Outcomes in Scleroderma Lung Disease: Results of Scleroderma Lung Study II
    Volkmann, Elizabeth R.
    Tashkin, Donald P.
    LeClair, Holly
    Roth, Michael D.
    Kim, Grace
    Goldin, Jonathan
    Clements, Philip J.
    Furst, Daniel E.
    Khanna, Dinesh
    ACR OPEN RHEUMATOLOGY, 2020, 2 (06) : 362 - 370
  • [33] Cyclophosphamide in scleroderma lung disease
    Andreu, Jose-Luis
    Silva, Lucia
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (11): : 1173 - 1173
  • [34] The Scleroderma Lung Study II (SLS II) Shows That Both Oral Cyclophosphamide (CYC) and Mycophenolate Mofitil (MMF) Are Efficacious in Treating Progressive Interstitial Lung Disease (ILD) in Patients with Systemic Sclerosis (SSc)
    Clements, Philip J.
    Tashkin, Donald
    Roth, Michael
    Khanna, Dinesh
    Furst, Daniel E.
    Tseng, Chi-hong
    Volkmann, Elizabeth R.
    Elashoff, Robert
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [35] Lung Transplant Outcomes of Patients with Scleroderma with Interstitial Lung Disease and Patients with Scleroderma with Pulmonary Hypertension
    Charoenpong, P.
    Song, D.
    Daoud, N.
    Adedeji, A.
    Hansra, R.
    Mudigonda, G.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [36] Interstitial lung disease in scleroderma
    White, B
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2003, 29 (02) : 371 - +
  • [37] MYCOPHENOLATE MOFETIL (MMF) IN SCLERODERMA (SSc) ASSOCIATED INTERSTITIAL LUNG DISEASE (ILD) AND SKIN DISEASE - THE AUSTRALIAN EXPERIENCE
    Jayaweera, S.
    Sahhar, J.
    Englert, H.
    Proudman, S.
    Hill, C.
    Youssef, P.
    INTERNAL MEDICINE JOURNAL, 2011, 41 : 11 - 11
  • [38] Interstitial Lung Disease in Scleroderma
    Schoenfeld, Sara R.
    Castelino, Flavia V.
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2015, 41 (02) : 237 - +
  • [39] Clinical Course of Lung Physiology in Patients With Scleroderma and Interstitial Lung Disease Analysis of the Scleroderma Lung Study Placebo Group
    Khanna, Dinesh
    Tseng, Chi-Hong
    Farmani, Niloofar
    Steen, Virginia
    Furst, Daniel E.
    Clements, Philip J.
    Roth, Michael D.
    Goldin, Jonathan
    Elashoff, Robert
    Seibold, James R.
    Saggar, Rajeev
    Tashkin, Donald P.
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : 3078 - 3085
  • [40] Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease
    Strange, Charlie
    Bolster, Marcy B.
    Roth, Michael D.
    Silver, Richard M.
    Theodore, Arthur
    Goldin, Jonathan
    Clements, Philip
    Chung, Joanie
    Elashoff, Robert M.
    Suh, Robert
    Smith, Edwin A.
    Furst, Daniel E.
    Tashkin, Donald P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2008, 177 (01) : 91 - 98
12345